How Should We Treat Patients with Mild Asthma?

Asthma is one of the most common chronic respiratory diseases in the world. Despite advances in the understanding of the biologic characteristics of asthma and its treatment, many surveys continue to document suboptimal control in large proportions of patients around the world. 1,2 Both U.S. and int...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 380; no. 21; pp. 2064 - 2066
Main Author Wong, Gary W.K
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 23.05.2019
Subjects
Asthma
Eosinophils
Humans
Inflammation
Mometasone Furoate
Prevention programs
Respiratory diseases
Sputum
Tiotropium Bromide
United States > US
Online AccessGet full text

Cover

More Information
Summary:Asthma is one of the most common chronic respiratory diseases in the world. Despite advances in the understanding of the biologic characteristics of asthma and its treatment, many surveys continue to document suboptimal control in large proportions of patients around the world. 1,2 Both U.S. and international guidelines recommend the use of short-acting β 2 -agonists (SABAs) as needed for the treatment of mild intermittent asthma. 3,4 When symptoms become persistent, the recommended treatment is an inhaled glucocorticoid taken on a regular basis, so-called maintenance therapy, which should lead to reduced use of a SABA. In reality, patients tend to rely on as-needed SABAs . . .
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMe1905354